{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:06:23Z","timestamp":1783703183223,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>There is an ongoing controversial debate about the effectiveness of laser treatments in chronic central serous chorioretinopathy (cCSC). We performed a prospective non-randomized interventional study to learn about the effects of a subthreshold laser treatment (Topcon Endpoint Management\u2122, Topcon Healthcare Inc., Tokyo, Japan) in patients with cCSC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with cCSC and a minimum symptom duration of 4\u00a0months were included and treated with a standardized laser pattern covering the macular area. Retreatment was performed every 3\u00a0months if persistent subretinal fluid was observed. The primary endpoint was resolution of subretinal fluid at 6\u00a0months. Further outcome parameters included best corrected visual acuity, microperimetry, central macular and subfoveal choroidal thickness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 42 eyes of 39 patients were included. Mean patient age was 48\u2009\u00b1\u200910.6\u00a0years (range 25\u201367). Mean symptomatic time before inclusion into the study was 134\u2009\u00b1\u2009133.4\u00a0weeks (16\u2013518). Before inclusion, 78.6% of the patients had failed to resolve subretinal fluid under mineralocorticoid receptor antagonists and 14.3% had a recurrence after half-dose photodynamic therapy. Complete resolution of subretinal fluid was observed in 42.9% at 6\u00a0months and in 53.8% at 12\u00a0months after baseline. Central retinal thickness decreased from 398\u2009\u00b1\u2009135\u00a0\u00b5m to 291\u2009\u00b1\u200968\u00a0\u00b5m (p\u2009&lt;\u20090.001), subfoveal choroidal thickness changed slightly (430\u2009\u00b1\u2009116\u00a0\u00b5m to 419\u2009\u00b1\u2009113\u00a0\u00b5m, p\u2009=\u20090.026), microperimetry-derived macular function improved by 19.1\u2009\u00b1\u20094.7\u00a0dB to 21.3\u2009\u00b1\u20094.8\u00a0dB (p\u2009=\u20090.008) and mean BCVA improved by 4.9\u2009\u00b1\u20098.6 ETDRS letters (p\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The results show that the investigated laser treatment is effective in reducing subretinal fluid and leads to an improvement of functional parameters.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-021-05256-3","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T06:04:40Z","timestamp":1623305080000},"page":"3271-3281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Subthreshold laser therapy with a standardized macular treatment pattern in chronic central serous chorioretinopathy"],"prefix":"10.1007","volume":"259","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0753-2408","authenticated-orcid":false,"given":"Benedikt","family":"Schworm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Siedlecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie F.","family":"Keidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina R.","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Luft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried G.","family":"Priglinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"issue":"12","key":"5256_CR1","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0161-6420(96)30386-2","volume":"103","author":"RF Spaide","year":"1996","unstructured":"Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA (1996) Central serous chorioretinopathy in younger and older adults. Ophthalmology 103(12):2070\u20132079","journal-title":"Ophthalmology"},{"issue":"10","key":"5256_CR2","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1097\/iae.0000000000001443","volume":"37","author":"A Daruich","year":"2017","unstructured":"Daruich A, Matet A, Marchionno L, De Azevedo JD, Ambresin A, Mantel I, Behar-Cohen F (2017) Acute central serous chorioretinopathy: factors influencing episode duration. Retina 37(10):1905\u20131915. https:\/\/doi.org\/10.1097\/iae.0000000000001443","journal-title":"Retina"},{"key":"5256_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.12.048","author":"S Mrejen","year":"2019","unstructured":"Mrejen S, Balaratnasingam C, Kaden TR, Bottini A, Dansingani K, Bhavsar KV, Yannuzzi NA, Patel S, Chen KC, Yu S, Stoffels G, Spaide RF, Freund KB, Yannuzzi LA (2019) Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2018.12.048","journal-title":"Ophthalmology"},{"key":"5256_CR4","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","volume":"73","author":"TJ van Rijssen","year":"2019","unstructured":"van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, Sivaprasad S, Querques G, Downes SM, Fauser S, Hoyng CB, Piccolino FC, Chhablani JK, Lai TYY, Lotery AJ, Larsen M, Holz FG, Freund KB, Yannuzzi LA, Boon CJF (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.07.003","journal-title":"Prog Retin Eye Res"},{"issue":"10","key":"5256_CR5","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1097\/IAE.0b013e318297a07a","volume":"33","author":"E Bousquet","year":"2013","unstructured":"Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F (2013) Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 33(10):2096\u20132102. https:\/\/doi.org\/10.1097\/IAE.0b013e318297a07a","journal-title":"Retina"},{"issue":"2","key":"5256_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/tvst.5.2.2","volume":"5","author":"A Daruich","year":"2016","unstructured":"Daruich A, Matet A, Dirani A, Gallice M, Nicholson L, Sivaprasad S, Behar-Cohen F (2016) Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl Vis Sci Technol 5(2):2. https:\/\/doi.org\/10.1167\/tvst.5.2.2","journal-title":"Transl Vis Sci Technol"},{"issue":"2","key":"5256_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00417-016-3436-5","volume":"255","author":"TR Herold","year":"2017","unstructured":"Herold TR, Rist K, Priglinger SG, Ulbig MW, Wolf A (2017) Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR). Graefes Arch Clin Exp Ophthalmol 255(2):221\u2013229. https:\/\/doi.org\/10.1007\/s00417-016-3436-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10220","key":"5256_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/s0140-6736(19)32981-2","volume":"395","author":"A Lotery","year":"2020","unstructured":"Lotery A, Sivaprasad S, O\u2019Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U, Peto T, Rogers CA, Reeves BC (2020) Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet 395(10220):294\u2013303. https:\/\/doi.org\/10.1016\/s0140-6736(19)32981-2","journal-title":"Lancet"},{"issue":"6","key":"5256_CR9","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.survophthal.2010.02.005","volume":"55","author":"S Sivaprasad","year":"2010","unstructured":"Sivaprasad S, Elagouz M, McHugh D, Shona O, Dorin G (2010) Micropulsed diode laser therapy: evolution and clinical applications. Surv Ophthalmol 55(6):516\u2013530. https:\/\/doi.org\/10.1016\/j.survophthal.2010.02.005","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"5256_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3928\/23258160-20130909-08","volume":"44","author":"L Roisman","year":"2013","unstructured":"Roisman L, Magalhaes FP, Lavinsky D, Moraes N, Hirai FE, Cardillo JA, Farah ME (2013) Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg Lasers Imaging Retina 44(5):465\u2013470. https:\/\/doi.org\/10.3928\/23258160-20130909-08","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"8","key":"5256_CR11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3928\/23258160-20150909-08","volume":"46","author":"FT Kretz","year":"2015","unstructured":"Kretz FT, Beger I, Koch F, Nowomiejska K, Auffarth GU, Koss MJ (2015) Randomized clinical trial to compare micropulse photocoagulation versus half-dose verteporfin photodynamic therapy in the treatment of central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging Retina 46(8):837\u2013843. https:\/\/doi.org\/10.3928\/23258160-20150909-08","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"10","key":"5256_CR12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","volume":"125","author":"EHC van Dijk","year":"2018","unstructured":"van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE, Querques G, Downes SM, Hoyng CB, Boon CJF (2018) Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology 125(10):1547\u20131555. https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.021","journal-title":"Ophthalmology"},{"key":"5256_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","volume":"48","author":"A Daruich","year":"2015","unstructured":"Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82\u2013118. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.05.003","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"5256_CR14","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1167\/iovs.15-18981","volume":"57","author":"D Lavinsky","year":"2016","unstructured":"Lavinsky D, Wang J, Huie P, Dalal R, Lee SJ, Lee DY, Palanker D (2016) Nondamaging retinal laser therapy: rationale and applications to the macula. Invest Ophthalmol Vis Sci 57(6):2488\u20132500. https:\/\/doi.org\/10.1167\/iovs.15-18981","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"5256_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB (2019) Pachychoroid disease. Eye (Lond) 33(1):14\u201333. https:\/\/doi.org\/10.1038\/s41433-018-0158-4","journal-title":"Eye (Lond)"},{"issue":"12","key":"5256_CR16","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.oret.2019.08.002","volume":"3","author":"J Siedlecki","year":"2019","unstructured":"Siedlecki J, Schworm B, Priglinger SG (2019) The pachychoroid disease spectrum-and the need for a uniform classification system. Ophthalmol Retina 3(12):1013\u20131015. https:\/\/doi.org\/10.1016\/j.oret.2019.08.002","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"5256_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/iae.0000000000000742","volume":"36","author":"KK Dansingani","year":"2016","unstructured":"Dansingani KK, Balaratnasingam C, Naysan J, Freund KB (2016) En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina 36(3):499\u2013516. https:\/\/doi.org\/10.1097\/iae.0000000000000742","journal-title":"Retina"},{"issue":"1","key":"5256_CR18","doi-asserted-by":"publisher","first-page":"14689","DOI":"10.1038\/s41598-019-51268-9","volume":"9","author":"H Matsumoto","year":"2019","unstructured":"Matsumoto H, Kishi S, Mukai R, Akiyama H (2019) Remodeling of macular vortex veins in pachychoroid neovasculopathy. Sci Rep 9(1):14689. https:\/\/doi.org\/10.1038\/s41598-019-51268-9","journal-title":"Sci Rep"},{"issue":"3","key":"5256_CR19","first-page":"830","volume":"43","author":"U Schmidt-Erfurth","year":"2002","unstructured":"Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H (2002) Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 43(3):830\u2013841","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5256_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.04.022","author":"C Iovino","year":"2020","unstructured":"Iovino C, Au A, Chhablani J, Parameswarappa DC, Rasheed MA, Cennamo G, Cennamo G, Montorio D, Ho AC, Xu D, Querques G, Borrelli E, Sacconi R, Pichi F, Woodstock E, Sadda SR, Corradetti G, Boon CJF, van Dijk EHC, Loewenstein A, Zur D, Yoshimi S, Bailey Freund K, Peiretti E, Sarraf D (2020) Choroidal anatomical alterations following photodynamic therapy for chronic central serous chorioretinopathy: a multicenter study. Am J Ophthalmol. https:\/\/doi.org\/10.1016\/j.ajo.2020.04.022","journal-title":"Am J Ophthalmol"},{"key":"5256_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-04619-6","author":"TJ van Rijssen","year":"2020","unstructured":"van Rijssen TJ, Singh SR, van Dijk EHC, Rasheed MA, Vupparaboina KK, Boon CJF, Chhablani J (2020) Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-020-04619-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"5256_CR22","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1167\/iovs.10-5917","volume":"52","author":"C Sramek","year":"2011","unstructured":"Sramek C, Mackanos M, Spitler R, Leung LS, Nomoto H, Contag CH, Palanker D (2011) Non-damaging retinal phototherapy: dynamic range of heat shock protein expression. Invest Ophthalmol Vis Sci 52(3):1780\u20131787. https:\/\/doi.org\/10.1167\/iovs.10-5917","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"5256_CR23","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1167\/iovs.17-21610","volume":"58","author":"J Wang","year":"2017","unstructured":"Wang J, Quan Y, Dalal R, Palanker D (2017) Comparison of continuous-wave and micropulse modulation in retinal laser therapy. Invest Ophthalmol Vis Sci 58(11):4722\u20134732. https:\/\/doi.org\/10.1167\/iovs.17-21610","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"5256_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/IAE.0b013e3182993edc","volume":"34","author":"D Lavinsky","year":"2014","unstructured":"Lavinsky D, Sramek C, Wang J, Huie P, Dalal R, Mandel Y, Palanker D (2014) Subvisible retinal laser therapy: titration algorithm and tissue response. Retina 34(1):87\u201397. https:\/\/doi.org\/10.1097\/IAE.0b013e3182993edc","journal-title":"Retina"},{"issue":"2","key":"5256_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/iae.0000000000002810","volume":"41","author":"MC Savastano","year":"2021","unstructured":"Savastano MC, Rispoli M, Lumbroso B (2021) The incidence of neovascularization in central serous chorioretinopathy by optical coherence tomography angiography. Retina 41(2):302\u2013308. https:\/\/doi.org\/10.1097\/iae.0000000000002810","journal-title":"Retina"},{"issue":"3","key":"5256_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/iae.0000000000001580","volume":"38","author":"E Bousquet","year":"2018","unstructured":"Bousquet E, Bonnin S, Mrejen S, Krivosic V, Tadayoni R, Gaudric A (2018) Optical coherence tomography angiography of flat irregular pigment epithelium detachment in chronic central serous chorioretinopathy. Retina 38(3):629\u2013638. https:\/\/doi.org\/10.1097\/iae.0000000000001580","journal-title":"Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05256-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05256-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05256-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T06:25:07Z","timestamp":1634538307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05256-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["5256"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05256-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"25 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was approved by the ethics committee of the Ludwig Maximilian University Munich (identifier 17\u2013879). All patients provided written informed consent before entering the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No author reports any financial interest related to this study.BS received previous speaker fees and travel expenses from Novartis Pharma GmbH and Topcon Corporation. JS received previous speaker fees and travel expenses from Novartis Pharma GmbH, Carl Zeiss Meditec AG, Oculentis OSD Medical GmbH and Pharm-Allergan GmbH. JS received personal consultation fees from Bayer AG. Jakob Siedlecki received travel support from Oertli AG. LFK received income from honoraria as a lecturer from Recordati Pharma GmbH. TH received income from honoraria as a lecturer from\u00a0Novartis GmbH, Bayer AG and Pharm-Allergan GmbH. NL received income from honoraria as a lecturer from Alcon Laboratories Inc., NIDEK Co. Ltd and CenterVue SpA. SP received previous speaker fees and\/or travel expenses from Novartis Pharma GmbH, Oertli AG, Bayer AG, Alcon Pharma GmbH and Pharm-Allergan GmbH.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}